|
|
|
|
Postmenopausal Levels of Endogenous Sex Hormones and Risk of Colorectal Cancer
_ Postmenopausal Levels of Endogenous Sex Hormones and Risk of Colorectal Cancer.
|
|
|
Insulin, Insulin-Like Growth Factor-I, and Risk of Breast Cancer in Postmenopausal Women
Journal of the National Cancer Institute Advance Access originally published online on December 30, 2008 JNCI Journal of the National Cancer Institute 2009 101(1):48-60; doi:10.1093/jnci/djn415 This Article All Versions of this Article: 101...
|
|
|
Medical News: ACE-011 Phase 1 Results Published In The Journal Of Bone And Mineral Research
Bones / Orthopaedics News Main Category: Bones / Orthopaedics Also Included In: Blood / Hematology email to a friend printer friendly view / write opinions rate article Current Article Ratings: Patient / Public: 5 (1 votes) Health...
|
|
|
Amgen Submits Biologics License Application for FDA Approval of Denosumab in Women With Postmenopausal Osteopo
Amgen Submits Biologics License Application for FDA Approval of Denosumab in Women With Postmenopausal Osteoporosis and in Patients Undergoing Hormone Ablation for Either Prostate or Breast Cancer 2009 JAN 11 - (NewsRx.com) --...
|
|
|
ACE-011 Phase 1 Results Published In The Journal Of Bone And Mineral Research
Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including bone, muscle and red blood cells and Celgene Corporation, today announced the publication of the ACE...
|
|
|
Hyperinsulinemia May Be Risk Factor for Postmenopausal Breast Cancer
_ Hyperinsulinemia May Be Risk Factor for Postmenopausal Breast Cancer.
|
|
|
Amgen Submits Biologics License Application for FDA Approval of Denosumab in Women With Postmenopausal Osteopo
Amgen Inc.announced submission of a Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA) for denosumab, an investigational RANK Ligand inhibitor. The indications for which Amgen is seeking FDA approval...
|
|
|
Postmenopausal bleeding
While there can be many explanations for the cause of postmenopausal bleeding, any woman who experiences bleeding after the onset of menopause should take care to see her medical provider as soon as possible.Such bleeding may be painful...
|
|
|
Amgen submits BLA for Denosumab
Amgen Inc has submitted a Biologics License Application (BLA) to the US Food and Drug Administration (FDA) for denosumab, an investigational RANK Ligand inhibitor.The indications for which Amgen is seeking FDA approval are treatment and...
|
|
|
Amgen Submits Biologics License Application for FDA Approval of Denosumab in Women With Postmenopausal Osteopo
THOUSAND OAKS, Calif., Dec.19 /PRNewswire-FirstCall/ -- Amgen Inc. ( NASDAQ:AMGN) , today announced submission of a Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA) for denosumab, an investigational...
|
|
|
Amgen submits biologics license application for FDA approval of Denosumab
Biotechnology major Amgen has submitted a Biologics License Application (BLA) with the Food and Drug Administration (FDA) for denosumab, an investigational RANK Ligand inhibitor.Denosumab is the first fully human monoclonal antibody in...
|
|
|
Amgen (AMGN) Submits Biologics License Application for FDA Approval of Denosumab in Women With Postmenopausal
THOUSAND OAKS, Calif., Dec.19 /PRNewswire-FirstCall/ -- Amgen Inc. , today announced submission of a Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA) for denosumab, an investigational RANK Ligand...
|
|
|
Amgen Submits Biologics License Application for FDA Approval of Denosumab in Women With Postmenopausal Osteopo
THOUSAND OAKS, Calif., Dec.19 /PRNewswire-FirstCall/ -- Amgen Inc. , today announced submission of a Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA) for denosumab, an investigational RANK Ligand...
|
|
|
Amgen Submits Biologics License Application for FDA Approval of Denosumab in Women With Postmenopausal Osteopo
THOUSAND OAKS, Calif., Dec.19 /PRNewswire-FirstCall/ -- Amgen Inc. , today announced submission of a Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA) for denosumab, an investigational RANK Ligand...
|
|
|
Amgen Submits Biologics License Application for FDA Approval of Denosumab in Women With Postmenopaus
Amgen Inc., today announced submission of a Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA) for denosumab, an investigational RANK Ligand inhibitor. The indications for which Amgen is seeking FDA...
|
|
|
Amgen Submits Biologics License Application for FDA Approval of Denosumab in Women With Postmenopausal Osteopo
THOUSAND OAKS, Calif.'Two Phase 3 pivotal studies with fracture endpoints, in the PMO and prostate cancer settings, demonstrated denosumab's ability to reduce fracture, and all six studies showed denosumab's ability to increase bone...
|
|
|
Amgen Submits Biologics License Application for FDA Approval of Denosumab in Women With Postmenopausal Osteopo
THOUSAND OAKS, Calif., Dec.19 /PRNewswire-FirstCall/ -- Amgen Inc. , today announced submission of a Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA) for denosumab, an investigational RANK Ligand...
|
|
|
Amgen Submits Biologics License Application for FDA Approval of Denosumab in Women With Postmenopausal Osteopo
THOUSAND OAKS, Calif., Dec.19 /PRNewswire-FirstCall/ -- Amgen Inc. , today announced submission of a Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA) for denosumab, an investigational RANK Ligand...
|
|
|
::: Amgen Submits Biologics License Application for FDA Approval of Denosumab in Women With Postmenopausal Ost
THOUSAND OAKS, Calif., Dec.19 /PRNewswire-FirstCall/ -- Amgen Inc. (NASDAQ:AMGN), today announced submission of a Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA) for denosumab, an investigational...
|
|
|
Amgen Submits Biologics License Application for FDA Approval of Denosumab in Women With Postmenopausal Osteopo
THOUSAND OAKS, Calif., Dec.19 /PRNewswire-FirstCall/ -- Amgen Inc. (Nasdaq: AMGN), today announced submission of a Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA) for denosumab, an investigational...
|
|
|
Amgen Submits Biologics License Application for FDA Approval of Denosumab in Women With Postmenopausal Osteopo
THOUSAND OAKS, Calif., Dec.19 (HSMN NewsFeed) -- Amgen Inc. (Nasdaq: AMGN ), today announced submission of a Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA) for denosumab, an investigational RANK...
|
|
|
Amgen Submits Biologics License Application for FDA Approval of Denosumab in Women With Postmenopausal Osteopo
THOUSAND OAKS, Calif., Dec.19 /PRNewswire-FirstCall/ -- Amgen Inc. , today announced submission of a Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA) for denosumab, an investigational RANK Ligand...
|
|
|
Amgen Submits Biologics License Application for FDA Approval of Denosumab in Women With Postmenopausal Osteopo
THOUSAND OAKS, Calif., Dec.19 /PRNewswire-FirstCall/ -- Amgen Inc. , today announced submission of a Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA) for denosumab, an investigational RANK Ligand...
|
|
|
Amgen Submits Biologics License Application for FDA Approval of Denosumab in Women With Postmenopaus
THOUSAND OAKS, Calif., Dec.19 /PRNewswire-FirstCall/ -- Amgen Inc. 'Two Phase 3 pivotal studies with fracture endpoints, in the PMO and prostate cancer settings, demonstrated denosumab's ability to reduce fracture, and all six studies...
|
|
|
Rx Product News: Profile: A Closer Look at New FDA Actions: Actonel
Procter & Gamble's and sanofi-aventis' Actonel On April 22, 2008, the FDA approved the use of Actonel (risedronate sodium) 150-mg tablets as a once-monthly dose to treat and prevent postmenopausal osteoporosis.1 Actonel's original...
|
